Quan Dong Nguyen, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 4 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · County of Santa Clara
Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
22 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G144498 · Current
Licensed to practise in California · since 2016 · expires 2028-07-31 · University of Pennsylvania School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$37,431
Medicare paid this office $37,431 for 147 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 127 | $22,625 | $117 |
| Imaging of retina | 104 | $2,767 | $21 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 54 | $2,256 | $36 |
| Extended exam of the back part of the eye with retinal drawing | 56 | $1,209 | $19 |
| Measurement of retinal and optic nerve function | 24 | $689 | $29 |
See all 8 services
| Long return visit (40+ min) | 127 | $22,625 | $117 |
| Imaging of retina | 104 | $2,767 | $21 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 54 | $2,256 | $36 |
| Extended exam of the back part of the eye with retinal drawing | 56 | $1,209 | $19 |
| Measurement of retinal and optic nerve function | 24 | $689 | $29 |
| Measurement of retinal and optic nerve function targeting multiple separate locations | 24 | $645 | $27 |
| Exam of visual field with extended testing | 18 | $449 | $24 |
| Photography of content of eyes | 35 | $99 | $3 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
147 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 8% · Women 65% · Also on Medicaid 29% · Health risk score 1.25. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 65% · Diabetes 35% · Chronic kidney disease 20% · Depression 18% · Coronary heart disease 16% · Atrial fibrillation 15% · Heart failure 13% · Cancer 13% · COPD 10% · Stroke 9%.
The office billed $173,514, Medicare allowed $51,304 and paid $37,431; for 625 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 147 | 625 | 72 | 1.25 | $173,514 | $37,431 |
| 2023 | 129 | 791 | 72 | 1.20 | $227,454 | $51,320 |
| 2022 | 141 | 1,006 | 71 | 1.25 | $188,975 | $50,725 |
| 2021 | 143 | 1,286 | 71 | 1.46 | $212,098 | $61,784 |
| 2020 | 123 | 980 | 72 | 1.63 | $173,071 | $48,059 |
| 2019 | 104 | 901 | 72 | 1.61 | $147,808 | $41,430 |
| 2018 | 75 | 581 | 73 | 1.52 | $106,598 | $27,737 |
| 2017 | 47 | 329 | 73 | 1.68 | $50,730 | $14,276 |
| 2016 | 61 | 532 | 72 | 1.06 | $152,013 | $37,048 |
| 2015 | 86 | 807 | 70 | 1.19 | $208,357 | $52,352 |
| 2014 | 61 | 644 | 69 | 0.93 | $206,180 | $54,437 |
| 2013 | 64 | 454 | 73 | 0.91 | $134,869 | $38,480 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 111 | $25,991 | $121 |
| Imaging of retina | 108 | $4,250 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 49 | $2,454 | $37 |
| New patient visit (60+ min) | 11 | $1,837 | $167 |
| Extended exam of the back part of the eye with retinal drawing | 70 | $1,667 | $19 |
| Measurement of retinal and optic nerve function | 22 | $837 | $35 |
| Measurement of retinal and optic nerve function targeting multiple separate locations | 18 | $635 | $32 |
| Extended exam of the back part of the eye with optic nerve drawing | 33 | $490 | $13 |
| Exam of visual field with extended testing | 11 | $335 | $26 |
| Photography of content of eyes | 33 | $140 | $3 |
2022: 9 services
| Long return visit (40+ min) | 117 | $25,494 | $116 |
| Imaging of retina | 121 | $5,446 | $22 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 54 | $2,773 | $37 |
| Extended exam of the back part of the eye with optic nerve drawing | 105 | $2,455 | $13 |
| Return visit (30+ min) | 22 | $1,983 | $83 |
| Exam of visual field with extended testing | 22 | $590 | $22 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $500 | $29 |
| Extended exam of the back part of the eye with retinal drawing | 21 | $430 | $20 |
| Photography of content of eyes | 41 | $186 | $3 |
2021: 11 services
| Long return visit (40+ min) | 116 | $29,448 | $116 |
| Imaging of retina | 126 | $7,750 | $24 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 64 | $3,671 | $39 |
| Extended exam of the back part of the eye with optic nerve drawing | 100 | $2,861 | $13 |
| Injection of drug into eye | 11 | $2,629 | $91 |
| New patient visit (60+ min) | 14 | $2,407 | $172 |
| Return visit (30+ min) | 13 | $1,630 | $91 |
| Exam of visual field with extended testing | 22 | $809 | $23 |
| Extended exam of the back part of the eye with retinal drawing | 35 | $700 | $20 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $450 | $30 |
| Photography of content of eyes | 48 | $306 | $3 |
2020: 9 services
| Long return visit (40+ min) | 97 | $22,250 | $97 |
| Imaging of retina | 105 | $5,649 | $23 |
| Extended exam of the back part of the eye with retinal drawing | 93 | $3,246 | $20 |
| New patient visit (60+ min) | 21 | $3,148 | $150 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 34 | $2,198 | $42 |
| Photography of the retina | 13 | $1,002 | $20 |
| Extended exam of the back part of the eye with optic nerve drawing | 34 | $548 | $14 |
| Exam of visual field with extended testing | 13 | $429 | $27 |
| Photography of content of eyes | 47 | $266 | $3 |
2019: 8 services
| Long return visit (40+ min) | 81 | $18,741 | $95 |
| Imaging of retina | 87 | $4,794 | $23 |
| New patient visit (60+ min) | 19 | $2,894 | $152 |
| Examination of eye by ophthalmoscope with retinal drawing | 53 | $2,588 | $17 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | $2,462 | $40 |
| Examination of eye by ophthalmoscope with retinal drawing | 37 | $1,534 | $20 |
| Photography of the retina | 11 | $269 | $21 |
| Photography of content of eyes | 41 | $266 | $3 |
2018: 8 services
| Long return visit (40+ min) | 59 | $10,511 | $91 |
| New patient visit (60+ min) | 21 | $3,007 | $143 |
| Imaging of retina | 62 | $2,804 | $22 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 46 | $2,236 | $37 |
| Return visit (30+ min) | 22 | $2,190 | $63 |
| Examination of eye by ophthalmoscope with retinal drawing | 27 | $1,140 | $15 |
| Examination of eye by ophthalmoscope with retinal drawing | 25 | $832 | $18 |
| Photography of content of eyes | 32 | $158 | $3 |
2017: 8 services
| Long return visit (40+ min) | 34 | $4,583 | $100 |
| New patient visit (60+ min) | 17 | $2,517 | $148 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 39 | $1,800 | $40 |
| Return visit (30+ min) | 16 | $1,552 | $71 |
| Imaging of retina | 42 | $1,375 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 31 | $1,156 | $19 |
| Examination of eye by ophthalmoscope with retinal drawing | 15 | $748 | $18 |
| Photography of content of eyes | 14 | $64 | $3 |
2016: 8 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 43 | $7,839 | $110 |
| Return visit (30+ min) | 44 | $4,320 | $66 |
| Photography of the retina | 53 | $3,802 | $42 |
| Examination of eye by ophthalmoscope with retinal drawing | 48 | $2,437 | $18 |
| Long return visit (40+ min) | 12 | $1,678 | $88 |
| New patient visit (60+ min) | 12 | $1,615 | $135 |
| Imaging of retina | 14 | $437 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 11 | $436 | $20 |
2015: 10 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 59 | $14,937 | $132 |
| Photography of the retina | 74 | $7,177 | $50 |
| Return visit (30+ min) | 49 | $6,311 | $74 |
| Long return visit (40+ min) | 31 | $4,294 | $93 |
| Examination of eye by ophthalmoscope with retinal drawing | 67 | $3,827 | $19 |
| Established patient complete exam of visual system | 31 | $2,741 | $72 |
| Imaging of retina | 17 | $879 | $30 |
| Exam of visual field with extended testing | 11 | $698 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $505 | $20 |
| Photography of content of eyes | 20 | $476 | $12 |
2014: 9 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 52 | $15,495 | $129 |
| Photography of the retina | 56 | $6,213 | $49 |
| Long return visit (40+ min) | 28 | $4,360 | $97 |
| New patient visit (60+ min) | 21 | $2,956 | $141 |
| Examination of eye by ophthalmoscope with retinal drawing | 43 | $2,542 | $20 |
| Return visit (30+ min) | 27 | $2,527 | $74 |
| Established patient complete exam of visual system | 19 | $2,072 | $83 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $835 | $21 |
| Photography of content of eyes | 11 | $267 | $13 |
2013: 7 services
| Exam of retinal blood vessels using a special camera after injection of a dye | 43 | $8,669 | $99 |
| Established patient complete exam of visual system | 38 | $3,055 | $78 |
| Photography of the retina | 52 | $3,040 | $47 |
| Long return visit (40+ min) | 17 | $2,243 | $93 |
| Examination of eye by ophthalmoscope with retinal drawing | 50 | $2,081 | $21 |
| Examination of eye by ophthalmoscope with retinal drawing | 17 | $608 | $22 |
| Imaging of retina | 17 | $385 | $19 |
Medicaid work
$9,636 in 2024
Medicaid paid $9,636 for 147 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 113 | $8,704 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $488 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 22 | $444 |
| 2024 | 147 | 3 | 21 | $9,636 |
| 2023 | 419 | 5 | 34 | $17,898 |
| 2022 | 389 | 4 | 25 | $13,155 |
| 2021 | 641 | 4 | 30 | $21,227 |
| 2020 | 479 | 4 | 22 | $16,180 |
| 2019 | 132 | 3 | 19 | $7,134 |
| 2018 | 45 | 2 | 17 | $1,583 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 222 | $13,082 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 109 | $2,140 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 47 | $1,864 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 29 | $616 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 12 | $196 |
2022
| Long return visit (40+ min) | 134 | $8,186 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 153 | $2,949 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 32 | $1,255 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 70 | $765 |
2021
| Long return visit (40+ min) | 224 | $12,934 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 257 | $4,622 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 65 | $2,709 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 95 | $962 |
2020
| Long return visit (40+ min) | 194 | $10,901 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 170 | $3,253 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 99 | $1,903 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 16 | $124 |
2019
| Long return visit (40+ min) | 80 | $5,124 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 40 | $1,706 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 12 | $304 |
2018
| Long return visit (40+ min) | 18 | $1,072 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 27 | $511 |
Drugs they prescribed that Part D paid
$1,328,244
Pharmacies billed $1,328,244 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 546) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
355 generic and 191 brand-name prescriptions · $1,328,244 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Acthar | 12 | $953,219 | $79,435 |
| Humira(Cf) | 21 | $199,767 | $9,513 |
| Humira | 16 | $111,615 | $6,976 |
| Restasis | 13 | $12,051 | $927 |
| Prednisolone Acetate | 60 | $3,264 | $54 |
See all 15 drugs
| Acthar | 12 | $953,219 | $79,435 |
| Humira(Cf) | 21 | $199,767 | $9,513 |
| Humira | 16 | $111,615 | $6,976 |
| Restasis | 13 | $12,051 | $927 |
| Prednisolone Acetate | 60 | $3,264 | $54 |
| Mycophenolate Mofetil | 27 | $3,022 | $112 |
| Ketorolac Tromethamine | 76 | $1,910 | $25 |
| Acetazolamide | 24 | $1,864 | $78 |
| Methotrexate | 16 | $971 | $61 |
| Fluorometholone | 11 | $816 | $74 |
| Prednisone | 63 | $803 | $13 |
| Dorzolamide-Timolol | 36 | $564 | $16 |
| Brimonidine | 29 | $352 | $12 |
| Latanoprost | 25 | $212 | $8 |
| Timolol Maleate | 15 | $209 | $14 |
Year by year
| 2024 | 546 | 96 | 0% (0) | 35% | $1,328,244 |
| 2023 | 576 | 96 | 0% (0) | 37% | $1,516,460 |
| 2022 | 562 | 103 | 0% (0) | 28% | $607,085 |
| 2021 | 633 | 99 | 0% (0) | 37% | $1,069,482 |
| 2020 | 620 | 94 | 0% (0) | 39% | $795,537 |
| 2019 | 481 | 69 | 0% (0) | 36% | $680,174 |
| 2018 | 326 | 57 | 0% (0) | 33% | $312,044 |
| 2017 | 107 | 27 | 0% (0) | 22% | $8,019 |
| 2016 | 280 | 39 | 0% (0) | 39% | $20,226 |
| 2015 | 328 | 43 | 0% (0) | 35% | $22,500 |
| 2014 | 161 | 31 | 0% (0) | None | $9,040 |
| 2013 | 134 | 39 | 0% (0) | 33% | $11,361 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Acthar | 21 | $1,008,894 | $48,043 |
| Humira(Cf) | 28 | $231,789 | $8,278 |
| Humira | 23 | $201,269 | $8,751 |
| Restasis | 12 | $8,946 | $745 |
| Prednisolone Acetate | 62 | $3,583 | $58 |
| Alphagan P | 13 | $3,097 | $238 |
| Mycophenolate Mofetil | 15 | $2,252 | $150 |
| Ketorolac Tromethamine | 67 | $2,033 | $30 |
| Prednisone | 125 | $1,997 | $16 |
| Methotrexate | 20 | $1,196 | $60 |
| Dorzolamide-Timolol | 27 | $782 | $29 |
| Timolol Maleate | 14 | $412 | $29 |
| Latanoprost | 24 | $370 | $15 |
| Brimonidine | 20 | $241 | $12 |
| Erythromycin | 15 | $186 | $12 |
| Naproxen | 11 | $91 | $8 |
2022: 12 drugs
| Humira | 17 | $101,127 | $5,949 |
| Humira(Cf) | 12 | $90,002 | $7,500 |
| Humira(Cf) | 11 | $76,149 | $6,923 |
| Restasis | 17 | $14,213 | $836 |
| Mycophenolate Mofetil | 22 | $4,183 | $190 |
| Prednisolone Acetate | 49 | $3,082 | $63 |
| Prednisone | 134 | $3,023 | $23 |
| Methotrexate | 28 | $1,670 | $60 |
| Ketorolac Tromethamine | 53 | $1,583 | $30 |
| Dorzolamide-Timolol | 31 | $1,146 | $37 |
| Timolol Maleate | 23 | $253 | $11 |
| Latanoprost | 15 | $245 | $16 |
2021: 18 drugs
| Gammagard Liquid | Immune globulin | 13 | $395,620 | $30,432 |
| Humira(Cf) | None | 18 | $120,943 | $6,719 |
| Humira(Cf) | None | 11 | $68,932 | $6,267 |
| Restasis | None | 51 | $39,386 | $772 |
| Durezol | None | 11 | $6,734 | $612 |
| Prednisolone Acetate | None | 60 | $4,762 | $79 |
| Mycophenolate Mofetil | None | 23 | $4,051 | $176 |
| Doxycycline Hyclate | None | 20 | $3,482 | $174 |
| Ketorolac Tromethamine | None | 58 | $2,860 | $49 |
| Prednisone | None | 103 | $2,332 | $23 |
| Methotrexate | None | 25 | $1,892 | $76 |
| Dorzolamide-Timolol | None | 38 | $1,727 | $45 |
| Acetazolamide | None | 20 | $1,558 | $78 |
| Olopatadine | None | 11 | $268 | $24 |
| Latanoprost | None | 13 | $261 | $20 |
| Brimonidine | None | 11 | $188 | $17 |
| Timolol Maleate | None | 13 | $145 | $11 |
| Naproxen | None | 12 | $99 | $8 |
2020: 15 drugs
| Gammagard Liquid | Immune globulin | 13 | $382,165 | $29,397 |
| Restasis | None | 38 | $23,373 | $615 |
| Durezol | None | 21 | $9,118 | $434 |
| Mycophenolate Mofetil | None | 19 | $5,364 | $282 |
| Prednisolone Acetate | None | 62 | $5,128 | $83 |
| Acetazolamide | None | 24 | $2,991 | $125 |
| Ketorolac Tromethamine | None | 45 | $2,865 | $64 |
| Prednisone | None | 105 | $2,251 | $21 |
| Methotrexate | None | 18 | $1,517 | $84 |
| Dorzolamide-Timolol | None | 29 | $1,149 | $40 |
| Olopatadine | None | 14 | $857 | $61 |
| Doxycycline Hyclate | None | 16 | $610 | $38 |
| Latanoprost | None | 14 | $318 | $23 |
| Omeprazole | None | 22 | $264 | $12 |
| Sulfamethoxazole-Trimethoprim | None | 12 | $201 | $17 |
2019: 15 drugs
| Acthar | 11 | $458,295 | $41,663 |
| Humira | 15 | $82,591 | $5,506 |
| Restasis | 23 | $10,352 | $450 |
| Mycophenolate Mofetil | 29 | $4,853 | $167 |
| Combigan | 18 | $4,774 | $265 |
| Prednisolone Acetate | 47 | $3,502 | $75 |
| Prednisone | 108 | $2,030 | $19 |
| Brimonidine | 13 | $1,274 | $98 |
| Dorzolamide-Timolol | 28 | $1,111 | $40 |
| Doxycycline Hyclate | 19 | $1,000 | $53 |
| Ketorolac Tromethamine | 13 | $371 | $29 |
| Omeprazole | 20 | $366 | $18 |
| Latanoprost | 14 | $309 | $22 |
| Erythromycin | 12 | $160 | $13 |
| Timolol Maleate | 17 | $136 | $8 |
2018: 7 drugs
| Restasis | 20 | $7,469 | $373 |
| Mycophenolate Mofetil | 26 | $3,272 | $126 |
| Prednisolone Acetate | 30 | $1,998 | $67 |
| Prednisone | 68 | $1,792 | $26 |
| Ketorolac Tromethamine | 18 | $710 | $39 |
| Acyclovir | 16 | $416 | $26 |
| Timolol Maleate | 11 | $58 | $5 |
2017: 3 drugs
| Valacyclovir | 17 | $896 | $53 |
| Methotrexate | 11 | $832 | $76 |
| Prednisone | 22 | $759 | $35 |
2016: 9 drugs
| Valacyclovir | 33 | $2,859 | $87 |
| Durezol | 18 | $2,802 | $156 |
| Prednisolone Acetate | 38 | $1,962 | $52 |
| Methotrexate | 20 | $1,442 | $72 |
| Mycophenolate Mofetil | 16 | $1,080 | $68 |
| Prednisone | 32 | $763 | $24 |
| Diclofenac | 16 | $280 | $18 |
| Latanoprost | 16 | $167 | $10 |
| Timolol Maleate | 11 | $88 | $8 |
2015: 10 drugs
| Prolensa | 14 | $3,608 | $258 |
| Valacyclovir | 39 | $3,524 | $90 |
| Durezol | 17 | $2,888 | $170 |
| Prednisolone Acetate | 44 | $2,876 | $65 |
| Prednisone | 38 | $787 | $21 |
| Ketorolac Tromethamine | 16 | $663 | $41 |
| Methotrexate | 11 | $638 | $58 |
| Diclofenac | 22 | $516 | $23 |
| Latanoprost | 20 | $169 | $8 |
| Acyclovir | 12 | $104 | $9 |
2014: 4 drugs
| Prednisolone Acetate | 31 | $2,027 | $65 |
| Prednisone | 18 | $373 | $21 |
| Ketorolac Tromethamine | 11 | $246 | $22 |
| Diclofenac | 12 | $136 | $11 |
2013: 4 drugs
| Mycophenolate Mofetil | 20 | $2,333 | $117 |
| Ketorolac Tromethamine | 17 | $795 | $47 |
| Prednisolone Acetate | 23 | $757 | $33 |
| Prednisone | 13 | $297 | $23 |
Money from drug and device companies
$141,789 in 2025
| 2025 | 13 | 117 | $103,210 | $141,789 |
| 2024 | 16 | 103 | $71,345 | $95,699 |
| 2023 | 15 | 96 | $56,559 | $76,344 |
| 2022 | 17 | 87 | $74,024 | $121,219 |
| 2021 | 8 | 51 | $84,510 | $85,214 |
| 2020 | 12 | 51 | $115,818 | $140,817 |
| 2019 | 12 | 55 | $45,343 | $70,572 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mallinckrodt Hospital Products | Acthar | $85,436 | 57 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $26,047 | 16 payments
|
| Boehringer Ingelheim International GmbH | None | $16,350 | 4 payments
|
| Genentech USA | None | $3,565 | 2 payments
|
| Harrow Eye | Vevye | $2,937 | 2 payments
|
| Alcon Vision | None | $2,500 | 2 payments
|
See all 117 published payments
| Mallinckrodt Hospital Products | Meals · 2025-12-19 | Acthar | $11 |
| Mallinckrodt Hospital Products | Meals · 2025-12-19 | Acthar | $1 |
| Mallinckrodt Hospital Products | Meals · 2025-12-19 | Acthar | $12 |
| Mallinckrodt Hospital Products | Meals · 2025-12-18 | Acthar | $14 |
| Amgen | Meals · 2025-12-16 | Tavneos | $143 |
| Mallinckrodt Hospital Products | Meals · 2025-12-08 | Acthar | $39 |
| Mallinckrodt Hospital Products | Meals · 2025-11-17 | Acthar | $2 |
| Mallinckrodt Hospital Products | Meals · 2025-11-16 | Acthar | $38 |
| Apellis Pharmaceuticals | Meals · 2025-11-12 | Syfovre | $26 |
| Astellas Pharma US | Meals · 2025-11-11 | Izervay | $91 |
| ANI Pharmaceuticals | Meals · 2025-11-10 | Iluvien | $29 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-11-04 | Acthar | $11,040 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-11-04 | Acthar | $5,520 |
| Mallinckrodt Hospital Products | Travel · 2025-10-30 | Acthar | $156 |
| Mallinckrodt Hospital Products | Travel · 2025-10-29 | Acthar | $1,242 |
| Mallinckrodt Hospital Products | Travel · 2025-10-28 | Acthar | $507 |
| Mallinckrodt Hospital Products | Travel · 2025-10-28 | Acthar | $1,039 |
| Mallinckrodt Hospital Products | Meals · 2025-10-28 | Acthar | $146 |
| Regeneron Pharmaceuticals | Travel · 2025-10-28 | Eylea Hd | $12,849 |
| Regeneron Pharmaceuticals | Travel · 2025-10-28 | Eylea Hd | $26 |
| Alcon Vision | Consulting · 2025-10-23 | None | $500 |
| Astellas Pharma Global Development | Meals · 2025-10-21 | Izervay | $33 |
| Astellas Pharma Global Development | Meals · 2025-10-19 | Izervay | $137 |
| Mallinckrodt Hospital Products | Meals · 2025-10-13 | Acthar | $35 |
| Bausch & Lomb Americas | Meals · 2025-10-13 | Xipere | $111 |
| Apellis Pharmaceuticals | Meals · 2025-10-07 | Syfovre | $4 |
| Apellis Pharmaceuticals | Meals · 2025-10-06 | Syfovre | $28 |
| ANI Pharmaceuticals | Meals · 2025-10-01 | Purified Cortrophin Gel | $23 |
| ANI Pharmaceuticals | Meals · 2025-10-01 | Iluvien | $4 |
| Mallinckrodt Hospital Products | Meals · 2025-09-29 | Acthar | $40 |
| Alcon Vision | Consulting · 2025-09-18 | None | $2,000 |
| Regeneron Pharmaceuticals | Travel · 2025-09-16 | Eylea Hd | $261 |
| Regeneron Pharmaceuticals | Travel · 2025-09-16 | Eylea Hd | $219 |
| Regeneron Pharmaceuticals | Meals · 2025-09-12 | None | $47 |
| Regeneron Pharmaceuticals | Meals · 2025-09-10 | Eylea Hd | $150 |
| Regeneron Pharmaceuticals | Travel · 2025-09-09 | Eylea Hd | $180 |
| Mallinckrodt Hospital Products | Meals · 2025-08-26 | Acthar | $39 |
| ANI Pharmaceuticals | Meals · 2025-08-26 | Iluvien | $31 |
| Bausch & Lomb Americas | Meals · 2025-08-22 | Xipere | $108 |
| Mallinckrodt Hospital Products | Meals · 2025-08-20 | Acthar | $32 |
| Apellis Pharmaceuticals | Meals · 2025-08-14 | Syfovre | $4 |
| Apellis Pharmaceuticals | Meals · 2025-08-13 | Syfovre | $25 |
| Mallinckrodt Hospital Products | Travel · 2025-08-05 | Acthar | $184 |
| Mallinckrodt Hospital Products | Meals · 2025-08-05 | Acthar | $22 |
| ANI Pharmaceuticals | Meals · 2025-08-04 | Iluvien | $30 |
| Astellas Pharma Global Development | Meals · 2025-08-02 | Izervay | $110 |
| Genentech USA | Consulting · 2025-07-31 | None | $3,445 |
| Genentech USA | Meals · 2025-07-31 | None | $120 |
| Regeneron Pharmaceuticals | Meals · 2025-07-31 | Eylea Hd | $26 |
| Apellis Pharmaceuticals | Meals · 2025-07-31 | Syfovre | $29 |
| Mallinckrodt Hospital Products | Meals · 2025-07-30 | Acthar | $86 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-07-24 | Acthar | $13,800 |
| Mallinckrodt Hospital Products | Meals · 2025-07-23 | Acthar | $28 |
| Regeneron Pharmaceuticals | Travel · 2025-07-23 | Eylea Hd | $9,729 |
| Regeneron Pharmaceuticals | Travel · 2025-07-23 | Eylea Hd | $1,175 |
| Regeneron Pharmaceuticals | Travel · 2025-07-23 | Eylea Hd | $26 |
| Regeneron Pharmaceuticals | Travel · 2025-07-23 | Eylea Hd | $26 |
| Mallinckrodt Hospital Products | Travel · 2025-07-17 | Acthar | $727 |
| Mallinckrodt Hospital Products | Meals · 2025-07-17 | Acthar | $127 |
| Apellis Pharmaceuticals | Meals · 2025-07-09 | Syfovre | $20 |
| ANI Pharmaceuticals | Meals · 2025-07-02 | Yutiq | $27 |
| Bausch & Lomb Americas | Consulting · 2025-06-24 | None | $2,000 |
| ANI Pharmaceuticals | Meals · 2025-06-19 | Yutiq | $34 |
| Apellis Pharmaceuticals | Meals · 2025-06-18 | Syfovre | $13 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-06-17 | Acthar | $7,360 |
| Mallinckrodt Hospital Products | Travel · 2025-06-12 | Acthar | $962 |
| Mallinckrodt Hospital Products | Meals · 2025-06-12 | Acthar | $105 |
| Mallinckrodt Hospital Products | Meals · 2025-06-10 | Acthar | $37 |
| Apellis Pharmaceuticals | Meals · 2025-06-05 | Syfovre | $138 |
| Mallinckrodt Hospital Products | Meals · 2025-06-04 | Acthar | $80 |
| Mallinckrodt Hospital Products | Travel · 2025-06-04 | Acthar | $168 |
| Mallinckrodt Hospital Products | Meals · 2025-06-04 | Acthar | $20 |
| Mallinckrodt Hospital Products | Meals · 2025-06-04 | Acthar | $29 |
| ANI Pharmaceuticals | Meals · 2025-06-04 | Yutiq | $31 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-05-29 | Acthar | $13,800 |
| Mallinckrodt Hospital Products | Travel · 2025-05-23 | Acthar | $216 |
| Mallinckrodt Hospital Products | Meals · 2025-05-22 | Acthar | $143 |
| Mallinckrodt Hospital Products | Travel · 2025-05-22 | Acthar | $1,655 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-05-20 | None | $6,175 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-05-20 | None | $6,175 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-05-19 | None | $2,000 |
| Boehringer Ingelheim International GmbH | Consulting · 2025-05-19 | None | $2,000 |
| Mallinckrodt Hospital Products | Meals · 2025-05-15 | Acthar | $37 |
| Mallinckrodt Hospital Products | Meals · 2025-05-14 | Acthar | $135 |
| ANI Pharmaceuticals | Meals · 2025-05-12 | Yutiq | $30 |
| Astellas Pharma Global Development | Meals · 2025-05-06 | Izervay | $24 |
| Astellas Pharma US | Meals · 2025-05-06 | Izervay | $22 |
| Regeneron Pharmaceuticals | Meals · 2025-05-05 | Eylea Hd | $47 |
| Merck Sharp & Dohme | Consulting · 2025-05-05 | None | $1,410 |
| Apellis Pharmaceuticals | Meals · 2025-04-29 | Syfovre | $31 |
| Mallinckrodt Hospital Products | Travel · 2025-04-22 | Acthar | $116 |
| Mallinckrodt Hospital Products | Meals · 2025-04-22 | Acthar | $16 |
| Mallinckrodt Hospital Products | Meals · 2025-04-22 | Acthar | $40 |
| Mallinckrodt Hospital Products | Travel · 2025-04-22 | Acthar | $21 |
| Mallinckrodt Hospital Products | Meals · 2025-04-22 | Acthar | $20 |
| Regeneron Pharmaceuticals | Consulting · 2025-04-18 | Eylea | $1,105 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-04-17 | Acthar | $12,880 |
| Mallinckrodt Hospital Products | Meals · 2025-04-16 | Acthar | $39 |
| Mallinckrodt Hospital Products | Travel · 2025-04-12 | Acthar | $205 |
| Mallinckrodt Hospital Products | Meals · 2025-04-10 | Acthar | $129 |
| Mallinckrodt Hospital Products | Travel · 2025-04-10 | Acthar | $654 |
| Mallinckrodt Hospital Products | Travel · 2025-04-10 | Acthar | $841 |
| Mallinckrodt Hospital Products | Meals · 2025-04-10 | Acthar | $17 |
| ANI Pharmaceuticals | Meals · 2025-04-07 | Yutiq | $27 |
| Regeneron Pharmaceuticals | Meals · 2025-03-22 | Eylea Hd | $92 |
| Harrow Eye | Consulting · 2025-03-20 | Vevye | $2,800 |
| Bausch & Lomb Americas | Meals · 2025-03-20 | Miebo | $129 |
| Mallinckrodt Hospital Products | Meals · 2025-03-06 | Acthar | $33 |
| Mallinckrodt Hospital Products | Meals · 2025-03-04 | Acthar | $38 |
| Astellas Pharma US | Meals · 2025-02-27 | Izervay | $29 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-02-11 | Acthar | $9,200 |
| Mallinckrodt Hospital Products | Travel · 2025-02-06 | Acthar | $1,399 |
| Mallinckrodt Hospital Products | Meals · 2025-02-06 | Acthar | $120 |
| Mallinckrodt Hospital Products | Meals · 2025-02-03 | Acthar | $35 |
| Apellis Pharmaceuticals | Meals · 2025-01-28 | Syfovre | $27 |
| Harrow Eye | Meals · 2025-01-23 | Triesence | $137 |
| Regeneron Pharmaceuticals | Meals · 2025-01-21 | Eylea Hd | $91 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $95,699
| Mallinckrodt Hospital Products | Acthar | $50,558 | 29 payments
|
| Apellis Pharmaceuticals | Syfovre | $14,763 | 20 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $13,191 | 2 payments
|
| Merck Sharp & Dohme | None | $9,887 | 10 payments
|
| Ocular Therapeutix | Dextenza | $2,289 | 3 payments
|
| Boehringer Ingelheim International GmbH | None | $2,216 | 6 payments
|
| Regeneron Pharmaceuticals | Eylea | $1,483 | 5 payments
|
| Astellas Pharma US | Izervay | $421 | 9 payments
|
| Bausch & Lomb Americas | Xipere | $228 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $205 | 9 payments
|
| Abbvie | Ozurdex | $123 | 1 payment
|
| Astellas Pharma Global Development | Izervay | $103 | 2 payments
|
| Amgen | Pavblu | $85 | 1 payment
|
| Genentech | None | $67 | 2 payments
|
| Janssen Pharmaceuticals | None | $50 | 1 payment
|
| Thea Pharma | Iyuzeh | $29 | 1 payment
|
2023: $76,344
| Horizon Therapeutics plc | None | $21,000 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $16,811 | 9 payments
|
| Boehringer Ingelheim International GmbH | None | $15,491 | 16 payments
|
| Mallinckrodt Hospital Products | Acthar | $15,297 | 27 payments
|
| Regeneron Pharmaceuticals | Eylea | $4,671 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $1,245 | 2 payments
|
| Biogen | None | $369 | 9 payments
|
| Genentech | Lucentis | $309 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $307 | 6 payments
|
| Astellas Pharma US | None | $294 | 4 payments
|
| Alimera Sciences | Iluvien | $243 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $158 | 7 payments
|
| Ocular Therapeutix | Dextenza | $90 | 1 payment
|
| Janssen Research & Development | Whitestar Phaco Handpiece | $45 | 2 payments
|
| Genentech USA | Vabysmo | $14 | 1 payment
|
2022: $121,219
| Bausch & Lomb Americas | Xipere | $50,052 | 10 payments
|
| Mallinckrodt Hospital Products | Acthar | $37,286 | 27 payments
|
| Exeltis USA | Purified Cortrophin Gel | $11,108 | 13 payments
|
| Merck Sharp & Dohme | None | $9,712 | 11 payments
|
| Biogen | None | $4,772 | 3 payments
|
| Boehringer Ingelheim International GmbH | None | $2,399 | 6 payments
|
| Genentech | Vabysmo | $2,104 | 3 payments
|
| Samsung Bioepis Co. | None | $1,700 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $1,354 | 3 payments
|
| Spark Therapeutics | None | $155 | 2 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $149 | 1 payment
|
| Abbvie | Ozurdex | $124 | 1 payment
|
| Novartis Pharmaceuticals | None | $85 | 1 payment
|
| Alimera Sciences | Iluvien | $66 | 1 payment
|
| Coherus Biosciences | Cimerli | $58 | 2 payments
|
| Janssen Global Services | None | $47 | 1 payment
|
| Apellis Pharmaceuticals | None | $47 | 1 payment
|
2021: $85,214
| Mallinckrodt Hospital Products | Acthar | $52,142 | 24 payments
|
| Boehringer Ingelheim International GmbH | None | $8,491 | 16 payments
|
| Kala Pharmaceuticals | Eysuvis | $7,650 | 1 payment
|
| Novartis Pharma AG | Beovu | $7,524 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Visudyne | $3,781 | 3 payments
|
| Biogen | None | $3,400 | 1 payment
|
| Samsung Bioepis Co. | None | $1,275 | 1 payment
|
| Allergan | Ozurdex | $951 | 3 payments
|
2020: $140,817
| Aerie Pharmaceuticals | None | $44,240 | 5 payments
|
| Bausch & Lomb a division of Bausch Health US | Xipere | $25,791 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $18,949 | 16 payments
|
| Kala Pharmaceuticals | Eysuvis | $12,750 | 3 payments
|
| F. Hoffmann-La Roche AG | None | $10,740 | 2 payments
|
| Sanofi US Services | None | $10,335 | 1 payment
|
| Amgen | None | $6,972 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $6,218 | 9 payments
|
| Genentech | None | $2,530 | 1 payment
|
| Allergan | Ozurdex | $1,184 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $1,060 | 1 payment
|
| Novartis Pharmaceuticals | None | $49 | 1 payment
|
2019: $70,572
| Bausch & Lomb a division of Bausch Health US | Retisert | $24,140 | 6 payments
|
| Mallinckrodt Enterprises | Acthar | $22,307 | 15 payments
|
| F. Hoffmann-La Roche AG | Lucentis | $17,743 | 13 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $2,315 | 2 payments
|
| Kala Pharmaceuticals | None | $1,700 | 1 payment
|
| Amgen | None | $1,455 | 5 payments
|
| Aerie Pharmaceuticals | Rocklatan | $301 | 5 payments
|
| Genentech | Lucentis | $269 | 3 payments
|
| Alimera Sciences | Iluvien | $147 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $113 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $67 | 1 payment
|
| AbbVie | Humira | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Mallinckrodt Hospital Products Inc. · Acth As A Re-Emerging Therapy for Uveitis (the Acthar Study) · 2020 | Their institution | $294,576 |
| Mallinckrodt Hospital Products Inc. · Acth As A Re-Emerging Therapy for Uveitis (the Acthar Study) · 2024 | Their institution | $276,157 |
| Mallinckrodt Enterprises LLC · Acth As A Re-Emerging Therapy for Uveitis the Acthar Study · 2019 | Their institution | $267,802 |
| Mallinckrodt Hospital Products Inc. · Acth As A Re-Emerging Therapy for Uveitis (the Acthar Study) · 2022 | Their institution | $267,480 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Non Infectious Uveitis · 2020 | Their institution | $180,822 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Non Infectious Uveitis · 2019 | Their institution | $143,925 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020 | Their institution | $134,222 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2021 | Their institution | $35,857 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021 | Their institution | $34,215 |
| Roche TCRC, Inc. · Ro7200220 for Diabetic Macular Edema · 2020 | Their institution | $33,046 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Ph2a Pom in Npdr Bi 1467335 Vs Plc 12 Wk · 2019 | Their institution | $31,846 |
| Biogen, Inc. · An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (Aav2) Encoding Rab Escort Protein 1 (Rep1) · 2022 | This clinician | $31,200 |
| Aerie Pharmaceuticals, Inc. · A Multicenter, Open-Label, Safety and Proof-of-Concept Study To Assess Safety, Tolerability and Efficacy of Ar-1105 in Subjects With Macular Edema Due To Retinal Vein Occlusion (Rvo) · 2020 | Their institution | $30,238 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019 | Their institution | $28,735 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Non Infectious Uveitis · 2021 | Their institution | $28,256 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Srd Mrd Iia · 2022 | Their institution | $25,687 |
| Boehringer Ingelheim International GmbH · Crimson: A Multicentre, Randomised, Sham-Controlled (and Active Controlled in the USA), Double-Masked, 72-Week Trial To Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal Bi 764524 in Patients With Moderately Severe To Severe Non-Proliferative Diabetic Retinopathy · 2025 | Their institution | $25,443 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2023 | Their institution | $22,213 |
| Aerie Pharmaceuticals, Inc. · A Multicenter, Open-Label, Safety and Proof-of-Concept Study To Assess Safety, Tolerability and Efficacy of Ar-1105 in Subjects With Macular Edema Due To Retinal Vein Occlusion (Rvo) · 2019 | Their institution | $21,429 |
| Biogen, Inc. · An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (Aav2) Encoding Rab Escort Protein 1 (Rep1) · 2020 | This clinician | $21,400 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2022 | Their institution | $20,641 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pocp Npdr Study, 1 Dose Vs Placebo, 12 Wk · 2022 | Their institution | $17,815 |
| Boehringer Ingelheim International GmbH · Bi 764524 Phase 2b · 2024 | Their institution | $17,621 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Srd Mrd Pocm in Wamd · 2021 | Their institution | $16,471 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Srd Mrd Pocm in Wamd · 2023 | Their institution | $15,387 |
| Aerie Pharmaceuticals, Inc. · A Study Assessing Ar-13503 Implant Alone and in Combination With Aflibercept in Subjects With Namd Or Dme · 2019 | Their institution | $14,727 |
| Biogen, Inc. · A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using An Adeno-Associated Viral Vector (Aav2) Encoding Rab Escort Protein 1 (Rep1) · 2020 | This clinician | $13,800 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2023 | Their institution | $11,297 |
| Boehringer Ingelheim International GmbH · Eye Dmi Epidemiology Study · 2023 | Their institution | $5,748 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Srd/Mrd/Iia · 2024 | Their institution | $5,549 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Ph2a Pom in Npdr Bi 1467335 Vs Plc 12 Wk · 2020 | Their institution | $5,283 |
| F. Hoffmann-La Roche AG · Has the Time Come To Re-Evaluate the Treatment Paradigm for Diabetic Retinopathy · 2020 | This clinician | $5,114 |
| F. Hoffmann-La Roche AG · A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus, A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus · 2020 | This clinician | $4,225 |
| Boehringer Ingelheim International GmbH · Eye-Dmi Epidemiology Study · 2021 | Their institution | $3,928 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Srd/Mrd/Pocm in Wamd · 2021 | Their institution | $3,904 |
| Boehringer Ingelheim International GmbH · Eye-Dmi Epidemiology Study · 2024 | Their institution | $3,846 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Anti Sema3a for Dmi in Treated Pdr Patients · 2022 | Their institution | $3,833 |
| Roche TCRC, Inc. · O7200220 for Diabetica and Uveitica Macular Edema · 2021 | Their institution | $3,670 |
| Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2023 | This clinician | $3,380 |
| Boehringer Ingelheim Finland Ky · Anti-Sema3a for Dmi in Treated Pdr Patients · 2021 | Their institution | $3,304 |
| Boehringer Ingelheim International GmbH · Eye Dmi Epidemiology Study · 2022 | Their institution | $2,805 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Srd Mrd Pocm in Wamd · 2023 | Their institution | $2,746 |
| EyePoint Pharmaceuticals US, Inc. · Safety and Efficacy of An Injectable Fluocinolone Acetonide Intravitreal Insert · 2019 | Their institution | $2,108 |
| F. Hoffmann-La Roche AG · Harbor 1 · 2023 | This clinician | $1,961 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Srd Mrd Pocm in Wamd · 2022 | Their institution | $1,784 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2024 | This clinician | $1,665 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2025 | This clinician | $1,500 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2021 | This clinician | $905 |
| Boehringer Ingelheim Finland Ky · Srd/Mrd/Iia · 2021 | Their institution | $860 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Srd/Mrd/Pocm in Wamd · 2020 | Their institution | $839 |
| Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2021 | This clinician | $812 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2023 | This clinician | $411 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Anti-Sema3a for Dmi in Treated Pdr Patients · 2024 | Their institution | $67 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Non Infectious Uveitis · 2019 | This clinician | $61 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487608766
- Licence
- CA G144498, MD D53275California G144498: Current · expires 2028-07-31
- Trained
- Perelman School of Med at the University of Pennsylvania, 1994
- Group
- Stanford Health Care · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- MD 155300300
- Taxonomy
- Federal specialty code 207WX0108X (207WX0108X); Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2006-05-20
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.